Vaidehikrishnan

Principal Research Scientist at DUKE- NUS, Singapore. Interested in CML- biomarker discovery and therapeutic development

[Gaurav Narula MD @DrGauravNarula]

A dazzling array of First-in-Human NK cell based trials by the thought and action leader in the field @lab_rezvani
So much done in the last decade and she’s just getting started
Wonderful session at @SACT2025

[Bobby Ranjan @bbbranjan]

An incredible story that captures the imagination + painstakingly laborious scientific rigour = the recipe for great science👌
Huge congratulations to @a_denboba @hackettlab and everyone involved 🎉🙌

[Vaidehikrishnan @Vaidehikrishna4]

@RaviBha65448036 @JCO_ASCO Congratulations on this very important work!

[International CML Foundation @icmlf]

Thank you to our team of climbers, donors and sponsors who have made this event possible so that we can continue our vital work towards improving outcomes for all #CML patients and moving us closer towards finding a cure.
#curecml

[Vaidehikrishnan @Vaidehikrishna4]

@icmlf Hearty Congratulations to all the climbers!

[Vaidehikrishnan @Vaidehikrishna4]

@JohnJosonNg @Pr_Cabotaje @gradmap_ph All the best Joson to you and the team!

[International CML Foundation @icmlf]

We're excited to announce the 2023 iCMLf Prize winners! Congratulations to Professor Jerry Radich (Rowley Prize), Professor François Guilhot (Goldman Prize), Professor Iryna Dyagil & Dr Kostyantyn Kotlyarchuk (iCMLf Prize). Learn more: https://t.co/1RaH4N6ruF @ESHaematology

[Vaidehikrishnan @Vaidehikrishna4]

@asharmaiisc Thanks very much Ankur!

[Vaidehikrishnan @Vaidehikrishna4]

We are very happy to share our latest #singlecell study on identifying the features of primary tyrosine kinase inhibitor (TKI) resistance at the time of chronic myeloid leukemia (#CML) diagnosis/1

[Vaidehikrishnan @Vaidehikrishna4]

@braincrank_nr @im_enzee @fschmidt92 @BloodJournal Thanks, yes indeed it was a very fun collaboration!

[International CML Foundation @icmlf]

Join us & Professor Susan Branford March 30 for the iCMLf Conversation ‘Genomics & Mutations in CML – Assessment & Risk’ as she shares her expertise on mutation assessment & significance in CML & the concept of genomically-based risk assessment. Learn more https://t.co/9iJS18gADS

[Vaidehikrishnan @Vaidehikrishna4]

@RaviBha65448036 Thank you very much.

[Vaidehikrishnan @Vaidehikrishna4]

@fschmidt92 @im_enzee @prasanna4321 @XiRen48198110 @yu_mengge @chanzhuen @Kian @imouyang @OwenRackham Last but not the least, we are extremely grateful to the CML #patients for consenting to the use of their samples for research. Moving forward, we hope to be able convert these scRNA-seq data into clinically meaningful tests for CML patients/10

[Vaidehikrishnan @Vaidehikrishna4]

@fschmidt92 @im_enzee @prasanna4321 @XiRen48198110 @yu_mengge @chanzhuen @Kian @imouyang @OwenRackham In short, molecular features correlating with TKI resistance outcome are readily discoverable at the time of CML diagnosis! /9